tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
Eric Le Berrigaud

Eric Le Berrigaud

Stifel Nicolaus
Wall Street Analyst
Ranked #3,616 out of 8,014 Analysts on TipRanks (#7,906 out of 21,455 overall experts)

Success Rate

42%
5 out of 12 Profitable Transactions

Average Return

7.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Eric Le Berrigaud's ratings since 2019 and opened each position for the duration of 1 Year:
41.67% of your transactions would have been profitable with an average return of 7.4%

Stock Rating Distribution

14Ratings
78.57% Buy
21.43% Hold
0.00% Sell
Distribution of Eric Le Berrigaud's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Abivax SA
(GB:0RA9)
Rating Type:Buy
Dates:Dec 04, 2019 - Dec 04, 2020
Gain:119.00%
The most profitable rating made by Eric Le Berrigaud

Eric Le Berrigaud's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Abivax SA
Buy
Initiated
€37.50
(360.12% Upside)
100%
+119.00%
1
AstraZeneca
Buy
Reiterated
100%
+11.00%
1
Roche Holding AG
Buy
Initiated
$434.57
(30.09% Upside)
0%
-12.30%
1
GlaxoSmithKline
Hold
Initiated
2,125.00p
(50.83% Upside)
0.00%
2
AstraZeneca
Buy
Initiated
12,300.00p
(17.05% Upside)
50%
+4.75%
2
Innate Pharma SA
Buy
Initiated
$7.30
(162.76% Upside)
0%
-16.60%
3
Novo Nordisk
Buy
Reiterated
kr920.00
(19.17% Upside)
50%
+7.10%
2
Sanofi
Buy
Reiterated
$122.43
(45.49% Upside)
0%
-13.05%
2
List of latest recommendations made by Eric Le Berrigaud. Click to expand and see Eric Le Berrigaud's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More